Last reviewed · How we verify
Experimental Sequence CBA
At a glance
| Generic name | Experimental Sequence CBA |
|---|---|
| Also known as | Sequence CBA |
| Sponsor | Temple University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Food Effect and the Absorption Profile of Ibuprofen Modified-Release Tablets 800 mg (PHASE1)
- Food Effects on Milademetan Pharmacokinetics in Healthy Participants (EARLY_PHASE1)
- Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying (NA)
- Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental Sequence CBA CI brief — competitive landscape report
- Experimental Sequence CBA updates RSS · CI watch RSS
- Temple University portfolio CI